PLAINSBORO, N.J., Oct. 8, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has launched a new website for physicians that provides information and training on the use of its two tissue regenerative products, the INTEGRA® Dermal Regeneration Template and INTEGRA™ Bilayer Matrix Wound Dressing. The address of the web site is http://www.ILSTraining.com.

The new website trains physicians in the use of the INTEGRA® Dermal Regeneration Template and the INTEGRA™ Bilayer Matrix Wound Dressing in clinical practice. The site currently contains two modules. The first module presents valuable information about the use of the INTEGRA® Dermal Regeneration Template for treating burns and scar contractures. The second module discusses the use of the INTEGRA™ Bilayer Matrix Wound Dressing for the management of partial and full-thickness soft tissue trauma and chronic wounds. Upon completion of the online training course, a physician will be certified to use the products in surgery.

Training online provides physicians with flexibility and quick access to product information. The website offers links to the latest news and journal articles, product brochures, package inserts, reimbursement policies, product ordering information, and a sales specialist locator. Physicians may direct technical questions to Integra clinical personnel by way of the "submit a question" feature located in the site's FAQ section.

"By providing physicians with the latest clinical information and access to online training, we can help physicians give their patients a higher level of care," said Tom Tarca, Integra's Vice President of Marketing, Plastic and Reconstructive Surgery.

The INTEGRA® Dermal Regeneration Template is the first and only FDA approved dermal regenerative product for burn and reconstructive surgery. It induces organized regeneration of dermal tissue and creates functional flexible skin. The product is indicated for the post-excisional treatment of life threatening full-thickness or deep partial-thickness thermal injuries where sufficient autograft is not available at the time of excision or not desirable due to the physiological condition of the patient. It is also indicated for the repair of scar contractures when other therapies have failed, or when donor sites for repair are not sufficient or desirable due to the physiological condition of the patient. Integra estimates that the market opportunity for products used in plastic and reconstructive surgery to treat burns and scar contractures is approximately $220 million.

The INTEGRA™ Bilayer Matrix Wound Dressing is an advanced wound care device that is ideal for partial and full-thickness soft tissue trauma and chronic wounds. The product is highly conformable for various anatomical sites and demonstrates excellent performance in deep donor sites. It is indicated for the management of a wide variety of wounds, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds. Integra estimates that the market opportunity for products used to treat trauma and chronic wounds is approximately $400 million.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the use of our tissue-engineered products, including the INTEGRA® Dermal Regeneration Template and the INTEGRA™ Bilayer Matrix Wound Dressing. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use Integra's tissue engineered products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors Than May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

Maria Platsis
Director of Corporate Development and Investor Relations
(609) 936-2333
mplatsis@Integra-LS.com